EHA Unplugged

European Hematology Association
  • 0,0 (0)
  • Scienze biologiche
  • Ogni settimana

In these EHA-produced podcasts, experts share with you their hematology knowledge and stories. With "EHA Unplugged" we would like to give you the opportunity to unplug from your computer screen, while still learning, by listening to interviews, clinical cases, monologues, and more.

  1. How Experts Treat Multiple Myeloma

    5 gg fa

    How Experts Treat Multiple Myeloma

    In this episode, Prof. Pieter Sonneveld is joined by Prof. Meletios Dimopoulos and Prof. Evangelos Terpos to discuss the updated EHA–EMN (European Myeloma Network) guidelines for the diagnosis, treatment and follow-up of multiple myeloma.  The conversation explores how recent therapeutic advances—including 14 newly approved treatment regimens, CAR T-cell therapies, bispecific antibodies and antibody-drug conjugates—have reshaped the treatment landscape and informed the latest recommendations. The experts discuss the integration of novel prognostic tools such as minimal residual disease (MRD), circulating tumour cells and mass spectrometry, and their evolving role in risk stratification.  The episode also reviews key recommendations for frontline management and provides practical guidance for selecting therapies in relapsed and refractory multiple myeloma. Throughout the discussion, the speakers highlight how the updated guidelines support clinicians in navigating an increasingly complex therapeutic landscape.  Guests:  Prof. Meletios Dimopoulos and Prof. Evangelos Terpos   National and Kapodistrian University of Athens, Greece Host: Prof. Pieter Sonneveld Erasmus University Medical Center, Rotterdam, The Netherlands  Learn More What did you think of this podcast? Share your opinions with us in this short feedback survey. ⁠⁠⁠⁠⁠⁠⁠⁠Provide Feedback⁠⁠⁠⁠⁠⁠⁠⁠ Would you like to explore more eLearning or podcasts? Please visit the EHA Campus. ⁠⁠⁠⁠⁠⁠⁠⁠https://ehaedu.org/Campus⁠⁠⁠⁠⁠⁠⁠⁠ Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to. Follow EHA on Instagram: ⁠⁠⁠⁠⁠⁠⁠⁠https://www.instagram.com/EHA_Hematology/⁠⁠⁠⁠⁠⁠⁠⁠ Facebook: ⁠⁠⁠⁠⁠⁠⁠⁠https://e-h-a.link/facebook⁠⁠⁠⁠⁠⁠⁠⁠ LinkedIn: ⁠⁠⁠⁠⁠⁠⁠⁠https://www.linkedin.com/company/eha/⁠⁠⁠⁠⁠⁠⁠⁠ Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via ⁠⁠⁠⁠⁠⁠⁠⁠https://eha.news/subscribe⁠⁠⁠⁠⁠⁠

    36 min
  2. Where Are We Now With Immunotherapy in Multiple Myeloma?

    22 giu

    Where Are We Now With Immunotherapy in Multiple Myeloma?

    Explore the latest advancements in immunotherapies for multiple myeloma, including CAR T-cell therapy, bispecific antibodies, and antibody-drug conjugates.  In this episode, Dr. Paula Rodriguez Otero discusses the strategic sequencing of BCMA and explains why CAR-T cells should often precede bispecific antibodies to maximize efficacy while  managing toxicity. The episode highlights the potential for these therapies to replace transplants by inducing deep, durable responses. Dr. Otero also explores new targets like GPRC5D, offering insights into future treatment possibilities. Guests:  Dr Paula Rodríguez-Otero  Cancer Center Clínica Universidad de Navarra (CCUN), CIMA, CIBERONC, IDISNA, Pamplona, Spain   Host: Isabel Olivera Martinez, PhD Learn More What did you think of this podcast? Share your opinions with us in this short feedback survey. ⁠⁠⁠⁠⁠⁠⁠⁠Provide Feedback⁠⁠⁠⁠⁠⁠⁠⁠ Would you like to explore more eLearning or podcasts? Please visit the EHA Campus. ⁠⁠⁠⁠⁠⁠⁠⁠https://ehaedu.org/Campus⁠⁠⁠⁠⁠⁠⁠⁠ Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to. Follow EHA on Instagram: ⁠⁠⁠⁠⁠⁠⁠⁠https://www.instagram.com/EHA_Hematology/⁠⁠⁠⁠⁠⁠⁠⁠ Facebook: ⁠⁠⁠⁠⁠⁠⁠⁠https://e-h-a.link/facebook⁠⁠⁠⁠⁠⁠⁠⁠ LinkedIn: ⁠⁠⁠⁠⁠⁠⁠⁠https://www.linkedin.com/company/eha/⁠⁠⁠⁠⁠⁠⁠⁠ Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via ⁠⁠⁠⁠⁠⁠⁠⁠https://eha.news/subscribe⁠⁠⁠⁠⁠⁠

    23 min
  3. Menin Inhibitors to Treat Acute Myeloid Leukemia (AML)

    1 giu

    Menin Inhibitors to Treat Acute Myeloid Leukemia (AML)

    Get up to date on menin inhibitors, an emerging class of targeted therapies for acute myeloid leukemia (AML). Menin is a key component of the KMT2A (lysine methyltransferase 2A, formerly MLL1) complex, which plays a critical role in gene regulation, development, and cell cycle control. Small-molecule menin inhibitors have shown particular promise in KMT2A-rearranged (KMT2Ar) and NPM1-mutated AML, with two agents already receiving FDA breakthrough therapy designation.  In this episode, Dr Scott Armstrong and Prof Marc Raaijmakers explore the scientific rationale behind menin inhibition, identify which AML patient populations are most likely to benefit, and review the current clinical evidence supporting their use in defined molecular subtypes. Guests:  Dr Scott Armstrong  Dana-Farber Cancer Institute  Prof Marc Raaijmakers  Erasmus Medical Center Host: Isabel Olivera Martinez, PhD Learn More What did you think of this podcast? Share your opinions with us in this short feedback survey. ⁠⁠⁠⁠⁠⁠⁠Provide Feedback⁠⁠⁠⁠⁠⁠⁠ Would you like to explore more eLearning or podcasts? Please visit the EHA Campus. ⁠⁠⁠⁠⁠⁠⁠https://ehaedu.org/Campus⁠⁠⁠⁠⁠⁠⁠ Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to. Follow EHA on Instagram: ⁠⁠⁠⁠⁠⁠⁠https://www.instagram.com/EHA_Hematology/⁠⁠⁠⁠⁠⁠⁠ Facebook: ⁠⁠⁠⁠⁠⁠⁠https://e-h-a.link/facebook⁠⁠⁠⁠⁠⁠⁠ LinkedIn: ⁠⁠⁠⁠⁠⁠⁠https://www.linkedin.com/company/eha/⁠⁠⁠⁠⁠⁠⁠ Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via ⁠⁠⁠⁠⁠⁠⁠https://eha.news/subscribe⁠⁠⁠⁠⁠⁠

    20 min
  4. How Experts Treat HIV-associated Lymphomas

    13 mag

    How Experts Treat HIV-associated Lymphomas

    Get up to date with the EHA–ESMO guidelines on Human immunodeficiency virus (HIV)-associated Lymphomas.  In this episode, Prof. Kai Hubel, a key author of the guidelines, explains the importance of having dedicated recommendations for patients with HIV-associated lymphomas. He begins by discussing the prevalence of lymphomas in people living with HIV, then highlights that the modern CART HIV treatment should be combined with the lymphoma treatments.  This interview further provides practical guidance to navigate these detailed recommendations that cover key lymphoma subtypes including DLBCL, Burkitt lymphoma, plasmatic lymphoma, and more.  Finally, Prof Hubel advocates for the inclusion of people living with HIV in lymphoma clinical trials to increase evidence base on HIV-associated lymphomas and improve the care for this specific patient populations.  Link to the guideline: Human immunodeficiency virus‐associated Lymphomas: EHA–ESMO Clinical Practice Guideline for diagnosis, treatment and follow‐up - Hübel - 2024 - HemaSphere - Wiley Online Library  Guest:  Prof Kai Hübel  Department of Internal Medicine, Faculty of Medicine and University Hospital Cologne, Cologne, Germany Host: Isabel Olivera Martinez, PhD Learn More What did you think of this podcast? Share your opinions with us in this short feedback survey. ⁠⁠⁠⁠⁠⁠Provide Feedback⁠⁠⁠⁠⁠⁠ Would you like to explore more eLearning or podcasts? Please visit the EHA Campus. ⁠⁠⁠⁠⁠⁠https://ehaedu.org/Campus⁠⁠⁠⁠⁠⁠ Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to. Follow EHA on Instagram: ⁠⁠⁠⁠⁠⁠https://www.instagram.com/EHA_Hematology/⁠⁠⁠⁠⁠⁠ Facebook: ⁠⁠⁠⁠⁠⁠https://e-h-a.link/facebook⁠⁠⁠⁠⁠⁠ LinkedIn: ⁠⁠⁠⁠⁠⁠https://www.linkedin.com/company/eha/⁠⁠⁠⁠⁠⁠ Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via ⁠⁠⁠⁠⁠⁠https://eha.news/subscribe⁠⁠⁠⁠⁠⁠

    11 min
  5. Hematology Portraits: Associate Prof Meritxell Alberich Jordà

    7 mag

    Hematology Portraits: Associate Prof Meritxell Alberich Jordà

    Join Meritxell Alberich Jordà, an EHA Board member and a principal investigator from Prague, as she shares her journey to becoming a recognised research scientist in hematology, and the role EHA has played along the way. Her lab studies hematopoietic and leukemic stem cells, focusing on how disruptions in transcriptional regulation and inflammatory signalling drive the development and persistence of acute myeloid leukemia.    Meri reflects on how her early research interests evolved over time, how key career decisions shaped the questions she pursues today, and what she finds most rewarding about leading a lab. Tune in to hear what she wishes she’d known at the very beginning of her journey.  Guest: Associate Prof Meritxell Alberich Jordà Institute of Molecular Genetics of the Czech Academy of Sciences, Laboratory of Haematooncology Head, Prague, Czech Republic The Childhood Leukaemia Investigation Prague in the Department of Pediatric Haematology and Oncology, 2nd Faculty of Medicine, Charles University, University Hospital Motol, Prague, Czech Republic  Host: Isabel Olivera Martinez, PhD Learn More What did you think of this podcast? Share your opinions with us in this short feedback survey. ⁠⁠⁠Provide Feedback⁠⁠⁠ Would you like to explore more eLearning or podcasts? Please visit the EHA Campus. ⁠⁠⁠https://ehaedu.org/Campus⁠⁠⁠ Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to. Follow EHA on Instagram: ⁠⁠⁠https://www.instagram.com/EHA_Hematology/⁠⁠⁠ Facebook: ⁠⁠⁠https://e-h-a.link/facebook⁠⁠⁠ LinkedIn: ⁠⁠⁠https://www.linkedin.com/company/eha/⁠⁠⁠ Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via ⁠⁠⁠https://eha.news/subscribe⁠⁠⁠

    19 min
  6. How Experts Treat Large B-cell Lymphoma (LBCL)

    23 apr

    How Experts Treat Large B-cell Lymphoma (LBCL)

    Get up to date with the latest EHA Clinical Practice Guidelines for Large B-cell lymphoma (LBCL) (⁠Large B‐cell lymphoma (LBCL): EHA Clinical Practice Guidelines for diagnosis, treatment, and follow‐up - Thieblemont - 2025 - HemaSphere - Wiley Online Library).⁠  Prof Catherine Thieblemont and Prof Marie José Kersten, two key authors of the guidelines,  walk us through the recommendations for Large B-cell lymphoma, covering diagnosis, treatment, and follow-up. Gain insights into key diagnostic considerations including staging, biopsy techniques and the importance of molecular testing. Our guests explain treatment strategies for first-line and relapse/refractory patient populations, highlighting the practice-changing introduction of CAR T therapy in second-line for eligible patients. Finally, they discuss the disparities of access to innovative treatments across Europe and explore future perspectives of LBCL management in Europe and beyond.  Guests: Prof Catherine Thieblemont and Prof Marie José Kersten.   Professor Catherine Thieblemont from Saint-Louis Hospital in Paris.  Professor Marie José Kersten from Amsterdam University Medical Centers (UMC)  Learn More What did you think of this podcast? Share your opinions with us in this short feedback survey. ⁠⁠⁠⁠⁠Provide Feedback⁠⁠⁠⁠⁠ Would you like to explore more eLearning or podcasts? Please visit the EHA Campus. ⁠⁠⁠⁠⁠https://ehaedu.org/Campus⁠⁠⁠⁠⁠ Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to. Follow EHA on Instagram: ⁠⁠⁠⁠⁠https://www.instagram.com/EHA_Hematology/⁠⁠⁠⁠⁠ Facebook: ⁠⁠⁠⁠⁠https://e-h-a.link/facebook⁠⁠⁠⁠⁠ LinkedIn: ⁠⁠⁠⁠⁠https://www.linkedin.com/company/eha/⁠⁠⁠⁠⁠ Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via ⁠⁠⁠⁠⁠https://eha.news/subscribe⁠⁠⁠⁠⁠

    18 min
  7. Connecting Hematology Research and Real Life: Peter Kapitein

    10 apr

    Connecting Hematology Research and Real Life: Peter Kapitein

    In this episode of EHA Unplugged, patient advocate Peter Kapitein discusses the importance of connecting patients, researchers, and clinicians to accelerate cancer research and treatment. He shares insights from his work with Inspire2Live, focusing on collaboration, data ownership, affordability, and global access to innovative therapies.  Guest: Peter Kapitein Host: Isabel Olivera Martinez, PhD Learn More What did you think of this podcast? Share your opinions with us in this short feedback survey. ⁠⁠⁠⁠⁠⁠Provide Feedback⁠⁠⁠⁠⁠⁠ Would you like to explore more eLearning or podcasts? Please visit the EHA Campus. ⁠⁠⁠⁠⁠⁠https://ehaedu.org/Campus⁠⁠⁠⁠⁠⁠ Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to. Follow EHA on Instagram: ⁠⁠⁠⁠⁠⁠https://www.instagram.com/EHA_Hematology/⁠⁠⁠⁠⁠⁠ Facebook: ⁠⁠⁠⁠⁠⁠https://e-h-a.link/facebook⁠⁠⁠⁠⁠⁠ LinkedIn: ⁠⁠⁠⁠⁠⁠https://www.linkedin.com/company/eha/⁠⁠⁠⁠⁠⁠ Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via ⁠⁠⁠⁠⁠⁠https://eha.news/subscribe⁠⁠⁠⁠⁠⁠  Guest: Peter Kapitein Host: Isabel Olivera Martinez, PhD Learn More What did you think of this podcast? Share your opinions with us in this short feedback survey. ⁠⁠⁠⁠Provide Feedback⁠⁠⁠⁠ Would you like to explore more eLearning or podcasts? Please visit the EHA Campus. ⁠⁠⁠⁠https://ehaedu.org/Campus⁠⁠⁠⁠ Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to. Follow EHA on Instagram: ⁠⁠⁠⁠https://www.instagram.com/EHA_Hematology/⁠⁠⁠⁠ Facebook: ⁠⁠⁠⁠https://e-h-a.link/facebook⁠⁠⁠⁠ LinkedIn: ⁠⁠⁠⁠https://www.linkedin.com/company/eha/⁠⁠⁠⁠ Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via ⁠⁠⁠⁠https://eha.news/subscribe⁠⁠⁠⁠

    25 min
  8. How Experts Treat Peripheral T- and NK-cell Lymphomas

    3 apr

    How Experts Treat Peripheral T- and NK-cell Lymphomas

    Get up to date with the latest ESMO-EHA guideline for Peripheral T- and natural killer-cell lymphomas (Peripheral T‐ and natural killer‐cell lymphomas: ESMO‐EHA Clinical Practice Guideline for diagnosis, treatment, and follow‐up - d'Amore - 2025 - HemaSphere - Wiley Online Library) Prof Francesco D'Amore (Aarhus University, Denmark) and Prof Massimo Federico (University of Modena and Reggio Emilia, Italy). In this episode, two key authors of the guidelines walk us through the recommendations for these rare, biologically diverse, and often aggressive- peripheral T cell and NK cell lymphomas. Our guests explain the conscious effort of the guidelines panel to provide evidence based detailed recommendations for each subtype of PTCLs to improve diagnosis, treatment, and follow up. The emphasis is on moving away from “one size fits all” DLBCL style approach toward entity- adapted strategies. Throughout the conversation, they stress the need to read the full guideline – including the supplementary material – and the importance of a multidisciplinary approach by experienced hematopathologists, ideally in expert or reference centres to give patients the best chance of appropriate, modern therapy. GuestS: Prof Francesco D'Amore and Prof Massimo Federico. Professor Francesco D'Amore is a Clinical Professor and Chair of the Department of Hematology at Aarhus University in Denmark Professor Massimo Federico is a Senior Professor of Medical Oncology at the University of Modena and Reggio Emilia in Italy Host: Isabel Olivera Martinez, PhD Learn More What did you think of this podcast? Share your opinions with us in this short feedback survey. ⁠⁠⁠Provide Feedback⁠⁠⁠ Would you like to explore more eLearning or podcasts? Please visit the EHA Campus. ⁠⁠⁠https://ehaedu.org/Campus⁠⁠⁠ Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to. Follow EHA on Instagram: ⁠⁠⁠https://www.instagram.com/EHA_Hematology/⁠⁠⁠ Facebook: ⁠⁠⁠https://e-h-a.link/facebook⁠⁠⁠ LinkedIn: ⁠⁠⁠https://www.linkedin.com/company/eha/⁠⁠⁠ Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via ⁠⁠⁠https://eha.news/subscribe⁠⁠⁠

    30 min
Elenco completo (184)

Descrizione

In these EHA-produced podcasts, experts share with you their hematology knowledge and stories. With "EHA Unplugged" we would like to give you the opportunity to unplug from your computer screen, while still learning, by listening to interviews, clinical cases, monologues, and more.

Informazioni

  • Creatore
    European Hematology Association
  • Anni di attività
    2021 - 2026
  • Puntate
    184
  • Classificazione
    Contenuti adatti a tutti
  • Copyright
    © European Hematology Association
  • Sito web del podcast
    EHA Unplugged

Potrebbero piacerti anche…